Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharmaust Limited ( (AU:NUZ) ) just unveiled an announcement.
Neurizon Therapeutics director Marcus Hughes has increased his equity stake in the company through the on-market purchase of 750,000 fully paid ordinary shares at $0.08 per share, for a total consideration of $60,000. Following the transaction, Hughes directly holds 13,110,746 fully paid ordinary shares and 600,000 unlisted options exercisable at $0.20 each by 30 June 2032, in addition to indirect holdings via a family superannuation fund and his spouse, signalling continued personal financial commitment and alignment of interests with other shareholders.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.28 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a life sciences company operating in the biotechnology and therapeutics sector, focused on developing pharmaceutical treatments. The company is listed on the ASX and its shareholder base includes directors and their related entities, reflecting typical ownership and governance structures for an early- to mid-stage biotech company.
Average Trading Volume: 485,543
Technical Sentiment Signal: Sell
Current Market Cap: A$61.98M
See more data about NUZ stock on TipRanks’ Stock Analysis page.